- Home
- GAU vs MPLT Comparison
GAU vs MPLT Comparison
Compare GAU & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAU | MPLT |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.7M | 811.3M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | GAU | MPLT |
|---|---|---|
| Price | $2.43 | $29.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.08 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 2.7M | 285.9K |
| Earning Date | 05-13-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $82.77 | N/A |
| Revenue Next Year | $29.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $12.24 |
| 52 Week High | $3.62 | $33.28 |
Technical Indicators
Market Signals| Indicator | GAU | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 62.94 |
| Support Level | $2.38 | $15.34 |
| Resistance Level | $2.55 | N/A |
| Average True Range (ATR) | 0.11 | 2.82 |
| MACD | -0.00 | 0.23 |
| Stochastic Oscillator | 7.04 | 67.50 |
Price Performance
Historical ComparisonAbout GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About MPLT MapLight Therapeutics Inc.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.